Unexpected genetically determined immune dysregulation with liver involvement: GIMAP5 therapeutic dilemmas between targeted therapy and HSCT - Quiz - MDSpire

Unexpected genetically determined immune dysregulation with liver involvement: GIMAP5 therapeutic dilemmas between targeted therapy and HSCT

  • By

  • Mattia Moratti

  • Michele La Manna

  • Lucia Colucci

  • Cristina Cifaldi

  • Silvia Di Cesare

  • Gioacchino Andrea Rotulo

  • Beatrice Rivalta

  • Donato Amodio

  • Andrea Pietrobattista

  • Andrés Caballero-Oteyza

  • Elisabetta Lembo

  • Chiara Passarelli

  • Emma Concetta Manno

  • Michele Proietti

  • Gigliola Di Matteo

  • Giuseppe Palumbo

  • Caterina Cancrini

  • June 10, 2026

  • 0 min

Share

Original Source(s)

Unexpected genetically determined immune dysregulation with liver involvement: GIMAP5 therapeutic dilemmas between targeted therapy and HSCT

  • by Mattia Moratti, Michele La Manna, Lucia Colucci, Cristina Cifaldi, Silvia Di Cesare, Gioacchino Andrea Rotulo, Beatrice Rivalta, Donato Amodio, Andrea Pietrobattista, Andrés Caballero-Oteyza, Elisabetta Lembo, Chiara Passarelli, Emma Concetta Manno, Michele Proietti, Gigliola Di Matteo, Giuseppe Palumbo, Caterina Cancrini

  • June 10, 2026

Related Content

The Role of Platelets in the Advancement of Fatty Liver Disease Linked to Metabolic Dysfunction-Associated Steatohepatitis: A Review of Pathophysiological Mechanisms

Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.